BioSpace News Archive

- Combined company will generate well over $100 million of ARR and signals a significant transformation in the future of software and data management in research labs. - Enabling over one million scientists to improve research and lab efficiency. - Facilitating rapid data access and exchange between scientists around the world, ultimately giving customers a competitive edge.

XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs in advanced coronary artery disease, announced the closing of an additional $22.6 million financing.

Proceeds to Support Pivotal Program of AU-011 for the First Line Treatment of Choroidal Melanoma and Expansion of Virus-like Drug Conjugate (VDC) Platform in additional Ocular Oncology Indications and Solid Tumors

Jack Nathan Medical Corp., a provider of primary care medical clinics located in Walmart® Supercentres under the Jack Nathan Health® brand, announced the acquisition of its 8172 sq.

Biotech company SaNOtize Research & Development Corp., announced that it has received interim approval to sell its Nitric Oxide Nasal Spray, which protects users from viruses that enter the body through the upper nasal pathways, to the public in pharmacies in Israel, and has been registered to begin sales of NONS in New Zealand.

Sonnet BioTherapeutics Holdings, Inc., a biopharmaceutical company developing innovative targeted biologic drugs, announced the appointment of Richard Kenney, M.D. as Chief Medical Officer and Manuel Dafonseca, as Head of Clinical Operations, effective March 22, 2021.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, provided details of four presentations that were made at the Endocrine Society’s annual ENDO 2021 congress on the company’s product pipeline.

Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced that Rand Sutherland, MD, MPH, has been appointed President effective March 22, 2021,

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that it has entered into a definitive license agreement under which the company, through a subsidiary, has acquired additional global rights to a non-steroidal anti-inflammatory technology that forms the basis of the companys EB01 and EB02 drug candidates.

Calyx, the imaging and eClinical solutions and services provider most relied on for solving complex data challenges in clinical research, today announced an expansion to its Executive Leadership Team, appointing Dr. Stephen M. Bravo as its Chief Medical Officer (CMO).